ARS Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.43 Insider Own10.50% Shs Outstand95.43M Perf Week-3.82%
Market Cap561.24M Forward P/E- EPS next Y-2.17 Insider Trans0.00% Shs Float62.98M Perf Month-1.63%
Income-85.40M PEG- EPS next Q-0.32 Inst Own34.30% Short Float / Ratio1.30% / 4.57 Perf Quarter14.83%
Sales2.41M P/S232.98 EPS this Y-169.80% Inst Trans16.08% Short Interest0.82M Perf Half Y73.07%
Book/sh7.53 P/B0.80 EPS next Y-4.80% ROA-28.20% Target Price5.00 Perf Year-13.34%
Cash/sh2.87 P/C2.11 EPS next 5Y- ROE-29.60% 52W Range2.80 - 7.55 Perf YTD-9.31%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-16.50% Beta-
Dividend %- Quick Ratio67.90 Sales past 5Y- Gross Margin- 52W Low125.00% ATR0.48
Employees92 Current Ratio67.90 Sales Q/Q-73.30% Oper. Margin- RSI (14)55.93 Volatility6.29% 9.21%
OptionableYes Debt/Eq0.00 EPS Q/Q22.20% Profit Margin- Rel Volume0.19 Prev Close6.04
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume178.71K Price6.30
Recom3.00 SMA203.01% SMA5011.08% SMA20039.88% Volume4,032 Change4.30%
Nov-10-22 08:00AM
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.